Thursday 25 April 2019

US regulators finally approve potential blockbuster drug for AstraZeneca

(stock image)
(stock image) Business Desk

The decision by US regulators to finally approve AstraZeneca’s much-delayed excess potassium drug Lokelma gives the group another new medicine launch.

The US Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, twice previously, casting doubt over AstraZeneca’s decision to buy its original developer ZS Pharma for $2.7bn in 2015.

Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma’s rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.


Also in Business